Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Gary DuBois, M.D.

Co-Author

This page shows the publications co-authored by Steven DuBois and Kimberly Stegmaier.
Connection Strength

0.519
  1. Ushering in the next generation of precision trials for pediatric cancer. Science. 2019 Mar 15; 363(6432):1175-1181.
    View in: PubMed
    Score: 0.209
  2. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Mar; 52(3):324-7.
    View in: PubMed
    Score: 0.104
  3. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 03; 146:115-124.
    View in: PubMed
    Score: 0.060
  4. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869.
    View in: PubMed
    Score: 0.052
  5. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621.
    View in: PubMed
    Score: 0.050
  6. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.